Plasma YKL‐40, as a prognostic tumor marker in recurrent ovarian cancer

Dehn, Hannah; Høgdall, Estrid; Johansen, Julia S.; Jørgensen, Morten; Price, Paul A.; Engelholm, Svend Aage; Høgdall, Claus

doi:10.1034/j.1600-0412.2003.00010.x

Cited by 73 publications

(42 citation statements)

References 27 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no relationship between serum YKL-40 levels and LDH and performance status of the patients. The percentage of patients with extensive SCLC with elevated serum YKL-40 is comparable to the percentage of patients with metastatic breast, colorectal and ovarian carcinoma with elevated serum YKL-40 [19][20][21][22][23][24]. The present study also showed that an elevated serum YKL-40 level at time of diagnosis reflected increased lung cancer aggressiveness since patients with high serum YKL-40 had shorter [19][20][21][22][23][24].…”

Section: Discussionsupporting

confidence: 57%

“…Increased serum YKL-40 levels are found in patients with primary and metastatic breast carcinoma [18][19][20] and ovarian carcinoma [21,22], and in preand post-operative samples from patients with colorectal carcinoma [23,24]. It was found in these studies that high serum YKL-40 levels were related to short recurrence-free interval and poor survival of the patients.…”

Section: Introductionmentioning

confidence: 61%

See 1 more Smart Citation

High serum YKL-40 level in patients with small cell lung cancer is related to early death

et al. 2004

View full text Add to dashboard Cite

Summary YKL-40, a growth factor for connective tissue cells, is secreted by cancer cells and macrophages. Elevated serum YKL-40 in patients with metastatic carcinoma has been associated with poor prognosis. We evaluated serum YKL-40 in 131 patients with small cell lung cancer (SCLC). Twenty-two percent of the patients with limited disease and 40% of the patients with extensive disease had elevated serum YKL-40. The median survival was 5.1 months for patients with elevated serum YKL-40 and 9.0 months for patients with normal serum YKL-40. Patients with elevated serum YKL-40 had increased hazard for death within the first 6 months after the start of chemotherapy compared to patients with normal serum YKL-40 (HR = 2.06, P = 0.009). Multivariate Cox analysis including routine prognostic variables showed that serum YKL-40 (P = 0.02) is independent of prognostic variables for survival within the first 6 months. Studies are needed to determine the function of YKL-40 in SCLC.

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Introductionmentioning

confidence: 61%

High serum YKL-40 level in patients with small cell lung cancer is related to early death

et al. 2004

View full text Add to dashboard Cite

show abstract

“…1 Both tumor cells and tumor-associated macrophages produce YKL-40. 2 Plasma YKL-40 is high in patients with gastrointestinal, [3][4][5] breast, 6 lung, 7 prostate 8 and other cancer, [9][10][11] and is also associated with tumour burden and prognosis after a cancer diagnosis. 5,[12][13][14][15][16] Furthermore, high plasma YKL-40 predicts high risk of gastrointestinal cancer in the general population.…”

mentioning

confidence: 99%

Observational and genetic plasma YKL‐40 and cancer in 96,099 individuals from the general population

Kjærgaard

Nordestgaard

Johansen

et al. 2015

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Plasma YKL-40 is high in patients with cancer and in individuals who later develop cancer. Whether YKL-40 is only a marker or indeed a cause of cancer is presently unknown. We tested the hypothesis that observationally and genetically, high plasma YKL-40 is associated with high risk of cancer. For this purpose, we performed cohort and Mendelian randomization studies in 96,099 individuals from the Danish general population. Plasma levels of YKL-40 were measured in 21,643 and CHI3L1 rs4950928 was genotyped in 94,568 individuals. From 1943 through 2011, 2,291 individuals developed gastrointestinal cancer, 913 developed lung cancer, 2,863 women developed breast cancer, 1,557 men developed prostate cancer and 5,146 individuals developed other cancer. Follow-up was 100% complete. Multifactorially and CRP adjusted hazard ratio (HR) for gastrointestinal cancer was 1.82 (95%CI, 1.16-2.86) for 96-100% versus 0-33% YKL-40 percentile category. Corresponding HR were 1.71 (0.95-3.07) for lung cancer, but insignificant for breast cancer, prostate cancer and other cancers. CHI3L1 rs4950928 genotype was associated with plasmaYKL-40 levels, but not with risk of any cancer category. For gastrointestinal cancer, a doubling in YKL-40 was associated with a multifactorially and CRP adjusted observational HR of 1.14(1.05-1.23) for gastrointestinal cancer, but a corresponding genetic odds ratio of 1.06(0.94-1.18). For lung cancer, corresponding risk estimates were 1.11(1.00-1.22) observationally and 1.01(0.84-1.20) genetically. For other cancer categories, observational and genetic findings were insignificant. This study shows that high plasma YKL-40 levels were associated with high risk of gastrointestinal and likely of lung cancer, but genetic high levels were not.Inflammation plays an important role in cancer development and/or progression. 1 Both tumor cells and tumor-associated macrophages produce YKL-40. 2 Plasma YKL-40 is high in patients with gastrointestinal, 3-5 breast, 6 lung, 7 prostate 8 and other cancer, 9-11 and is also associated with tumour burden and prognosis after a cancer diagnosis. 5,[12][13][14][15][16] Furthermore, high plasma YKL-40 predicts high risk of gastrointestinal cancer in the general population. 17 Whether YKL-40 is only a marker of inflammation and cancer or plays a causal role in the development of cancer is presently unknown.A single nucleotide polymorphism in the proximal promoter of chitinase-3-like-1 (same as YKL-40; CHI3L1), rs4950928, accounts for 9.4% of the variance of plasma YKL-40. 18 MYC/MAX transcriptional factors bind better to the major than to the minor allele of rs4950928 in the gene promoter, 19 thereby presumably increasing CHI3L1 transcription and elevating plasma YKL-40 levels in carriers of the major versus minor allele. [20][21][22] We tested the hypothesis that observationally and genetically high plasma YKL-40 is associated with high risk of cancer. For this purpose, we performed cohort and Mendelian randomization studies in 96,099 individuals from the Danish general population...

show abstract

“…It was first isolated from porcine VSMC, which is highly induced during nodule formation, but the precise function of this gene is presently unknown. High serum expression of YKL-40 has been associated with poor prognosis in colorectal cancer (Cintin et al, 1999), glioblastoma multiforme (Tanwar et al, 2002), breast cancer (Johansen et al, 1995), ovarian cancer (Dehn et al, 2003), and lung cancer (Johansen et al, 2004). Consistent with the function of CLU, overexpression of YKL-40 has been implicated in increased migration and tissue remodeling.…”

Section: Discussionmentioning

confidence: 99%

Clusterin plays an important role in hepatocellular carcinoma metastasis

et al. 2005

View full text Add to dashboard Cite

To identify genes associated with tumor metastasis in hepatocellular carcinoma (HCC), gene expression profiles between a pair of primary HCC (H2-P) and their matched metastatic HCC (H2-M) were compared. Overexpression of clusterin (CLU) was found in H2-M cells. To determine the roles CLU played in HCC metastasis, CLU was transfected into H2-P cells. Overexpression of CLU in H2-P cells increased cell migration by twofold in vitro and formation of metastatic tumor nodules in liver by eightfold in vivo. To evaluate the correlation of CLU expression with HCC metastasis, the expression levels of CLU in HCCs were investigated using a tissue microarray (TMA) containing 104 pairs of primary HCCs and their matched metastases. The frequency of CLU overexpression increased significantly in metastatic HCCs (59.1%) compared with that in primary tumors (32.6%, Po0.001). To gain additional insight into the function of CLU, the expression profile of H2P-CLU was compared with vector-transfected H2-P cells by cDNA microarray. A total of 35 upregulated and 14 downregulated genes were detected in H2P-CLU. One of the upregulated genes known as YKL-40, which is implicated in matrix-remodeling and metastasis, was further studied using TMA. A significant correlation (Po0.001) between the expression levels of YKL-40 and CLU was observed, implying that the CLU-YKL-40 pathway may play an important role in HCC metastasis.

show abstract

Plasma YKL‐40, as a prognostic tumor marker in recurrent ovarian cancer

Abstract: High plasma YKL-40 is related to short survival in patients with recurrent ovarian cancer.

Cited by 73 publications

References 27 publications

High serum YKL-40 level in patients with small cell lung cancer is related to early death

High serum YKL-40 level in patients with small cell lung cancer is related to early death

Observational and genetic plasma YKL‐40 and cancer in 96,099 individuals from the general population

Clusterin plays an important role in hepatocellular carcinoma metastasis

Contact Info

Product

Resources

About